Sensors and Actuators A Physical, Год журнала: 2024, Номер 382, С. 116141 - 116141
Опубликована: Дек. 16, 2024
Язык: Английский
Biology, Год журнала: 2024, Номер 13(7), С. 519 - 519
Опубликована: Июль 12, 2024
Glycolipid metabolic disorders (GLMDs) are various resulting from dysregulation in glycolipid levels, consequently leading to an increased risk of obesity, diabetes, liver dysfunction, neuromuscular complications, and cardiorenal vascular diseases (CRVDs). In patients with GLMDs, excess caloric intake a lack physical activity may contribute oxidative stress (OxS) systemic inflammation. This study aimed review the connection between GLMD, OxS, metainflammation, onset CRVD. GLMD is due causing dysfunction synthesis, breakdown, absorption glucose lipids body, excessive ectopic accumulation these molecules. mainly neuroendocrine dysregulation, insulin resistance, metainflammation. many inflammatory markers defense cells play vital role related tissues organs, such as blood vessels, pancreatic islets, liver, muscle, kidneys, adipocytes, promoting lesions that affect interconnected organs through their signaling pathways. Advanced glycation end products, ATP-binding cassette transporter 1, Glucagon-like peptide-1, Toll-like receptor-4, sphingosine-1-phosphate (S1P) crucial since they glucolipid metabolism. The consequences this system organ damage morbidity mortality.
Язык: Английский
Процитировано
21
Neuroscience, Год журнала: 2025, Номер 567, С. 235 - 248
Опубликована: Янв. 5, 2025
Язык: Английский
Процитировано
1
Frontiers in Pharmacology, Год журнала: 2025, Номер 15
Опубликована: Янв. 20, 2025
Introduction Diabetic nephropathy (DN), a major complication of diabetes, presents with poor clinical outcomes and affects patients throughout their lifetime. α-Methyltryptophan (α-MT) is blocker the amino acid transporter. SLC6A14 also an inhibitor indoleamine 2,3-dioxygenase-1 (IDO1). Methods In this study, we employed nuclear magnetic resonance-based metabolomic approach to investigate therapeutic effects α-MT in db/db mouse model DN explore underlying molecular mechanisms. Results The results study demonstrated that significantly reduced urinary excretion albumin creatinine, improved kidney function, decreased renal fibrosis mice. Metabolomic analyses tissues urine samples indicated mice displayed increased activity enzyme IDO1, alongside pronounced metabolic disturbances. These disturbances are chiefly characterized by alterations metabolism, energy production pathways, membrane biochemical features, nicotinamide all which have been implicated mTOR signaling apoptotic pathways. Discussion Administration showed evidence IDO1 inhibition rectification dysfunctions concurrent suppression apoptosis. findings highlight potential as promising agent for diabetic nephropathy.
Язык: Английский
Процитировано
1
Colloids and Surfaces B Biointerfaces, Год журнала: 2025, Номер 249, С. 114492 - 114492
Опубликована: Янв. 5, 2025
Язык: Английский
Процитировано
0
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
Probiotics and Antimicrobial Proteins, Год журнала: 2025, Номер unknown
Опубликована: Март 3, 2025
Язык: Английский
Процитировано
0
iScience, Год журнала: 2025, Номер unknown, С. 112163 - 112163
Опубликована: Март 1, 2025
Infections, cancer, and trauma can cause life-threatening hyperinflammation. In the present study, using single-cell RNA sequencing of circulating immune cells, we found that mammalian target rapamycin (mTOR) pathway plays a critical role in myeloid cell regulation COVID-19 patients. Previously, developed an mTOR-inhibiting nanobiologic (mTORi-nanobiologic) efficiently targets cells their progenitors bone marrow. vitro, demonstrated mTORi-nanobiologics potently inhibit infection-associated inflammation human primary cells. Next, investigated vivo effect mouse models hyperinflammation acute respiratory distress syndrome. Using 18F-FDG uptake flow cytometry readouts, mTORi-nanobiologic therapy to reduce hematopoietic organ metabolic activity levels comparable those healthy control animals. Together, show regulating myelopoiesis with is compelling therapeutic strategy prevent deleterious infection-related complications.
Язык: Английский
Процитировано
0
Biochemical Pharmacology, Год журнала: 2025, Номер unknown, С. 116850 - 116850
Опубликована: Март 1, 2025
Breast cancer (BC) is a complex disease that affects millions of women worldwide. Its growing impact calls for advanced treatment strategies to improve patient outcomes. The PI3K/AKT/mTOR pathway key focus in BC therapy because it plays major role important processes like tumor growth, survival, and resistance treatment. Targeting this could lead better options present review explores how the becomes dysregulated BC, focusing on genetic changes PIK3CA mutations PTEN loss leads its aggravation. Current include use inhibitors targeting PI3K, AKT, mTOR with combination therapies showing promise overcoming drug improving effectiveness. Looking ahead, next-generation personalized plans guided by biomarker analysis may provide more accurate effective patients. Integrating these immunotherapy offers an exciting opportunity boost anti-tumor responses survival rates. This comprehensive summary current progress BC. It highlights future research directions therapeutic aimed at enhancing outcomes quality life.
Язык: Английский
Процитировано
0
Frontiers in Molecular Biosciences, Год журнала: 2025, Номер 12
Опубликована: Март 7, 2025
Backgrounds Non-small cell lung cancer (NSCLC), one kind of common malignant tumor, is accompanied by high morbidity and mortality. The effects related mechanisms rapamycin (Rapa) combined with osimertinib (Osi) in treating NSCLC are still unclear. Therefore, this study aims to investigate the Rapa Osi on NSCLC. Methods In A549 PC-9 cells, Cell Counting Kit-8 (CCK-8) assay was used select optimal administrative concentrations evaluate viability. Transwell flow cytometry were determine migration, cycle, apoptosis, level Reactive Oxygen Species (ROS), respectively. protein mRNA expression Matrix Metalloproteinase-9 (MMP9), Caspase-3, Microtubule-Associated Protein 1 Light Chain 3 II/I (LC3 II/I), beclin1, Sequestosome (p62), Poly (ADP-ribose) Polymerase (PARP), Mitogen-Activated Kinase (MAPK), Extracellular Signal-Regulated (ERK), B (Akt), Mammalian Target Rapamycin (mTOR) determined Western blot Quantitative Reverse Transcription Reaction (qRT-PCR). Results 0.5 μM μM, Osimertinib significantly decreased viability quantity migrated levels ROS, as well MMP9 p62, LC3 II/I, beclin1. combination two drugs markedly more effective than use alone. Conclusion conclusion, demonstrated that can inhibit regulate promote autophagy increase ROS PARP, MAPK/EKR, Akt/mTOR pathways providing a novel theoretical basis for their clinical treatment
Язык: Английский
Процитировано
0
Current Issues in Molecular Biology, Год журнала: 2025, Номер 47(4), С. 237 - 237
Опубликована: Март 28, 2025
Tazarotene, a retinoid derivative, is widely used in treating skin conditions such as psoriasis and acne. Recent studies have demonstrated its potential promising therapeutic agent for melanoma situ. Its primary mechanism of action involves the selective activation retinoic acid receptors (RAR-β RAR-γ), which play important roles regulating cell growth, differentiation, apoptosis. By activating these receptors, tazarotene influences expression several downstream inducible genes, tazarotene-induced gene-1 (TIG1), TIG2, TIG3. These genes crucial proliferation, invasiveness, immune responses tumor microenvironment. This review aims to provide comprehensive overview current status derivatives—particularly tazarotene—in treatment latest research regarding their molecular mechanisms. We will explore how suppresses growth through gene regulation mechanisms discuss role within Additionally, we assess advantages challenges using topical future clinical applications. contribute wider understanding tazarotene’s antitumor mechanisms, providing solid theoretical foundation option
Язык: Английский
Процитировано
0